All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

2024-07-23T10:32:52.000Z

How do recent systemic approvals influence treatment selection for patients with psoriatic disease?​

Jul 23, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new development in psoriatic disease.


How do recent systemic approvals influence treatment selection for patients with psoriatic disease?​

During the Psoriasis Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA. 

The recorded discussion was chaired by Paolo Gisondi, and featured Alice Gottlieb and Yukari Okubo. The steering committee discussed recent approvals of systemic agents for psoriatic disease, including efficacy and safety data of bimekizumab and deucravacitinib. They also spoke about how to avoid and treat oral candidiasis infections in patients treated with interleukin 17 inhibitors. 

Listen to this video as a podcast here:

How do recent systemic approvals influence treatment selection for patients with psoriatic disease?​

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
10 votes - 50 days left ...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox